Robustly, compared to the combination of low-level H2AFJ with low-level expression of PMT, TNFα-NF-κB, or IL6-STAT3 geneset, as well as other combinations, the scenario of combining high-level of H2AFJ with high-level expression of PMT, TNFα-NF-κB, or IL6-STAT3 geneset predicted a worse prognosis (Figure 5C) and shorter overall survival time (Figure 5D) in TCGA GBM patients. The gene discussed is IL6; the disease is glioblastoma.